Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04585490
Title Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Stanford University

lung non-small cell carcinoma


Carboplatin + Durvalumab + Pemetrexed Disodium


Carboplatin + Durvalumab + Paclitaxel

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.